by Non-PVC IV bags are used to administer fluids, blood, medication and nutrition to patients intravenously. These bags eliminate the release of toxic phthalate plasticizers that can leach from polyvinyl chloride (PVC) based bags. The rising concerns regarding effects of medical plastics on human health and environment have led to surge in demand for non-PVC IV bags. Non-PVC IV bags offer advantages like being DEHP-free, latex-free and are manufactured using eco-friendly polymers like ethylene vinyl acetate. With growing prevalence of chronic diseases requiring intravenous therapeutics, the IV bags market has gained prominence. According to World Health Organization, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. The global Non-PVC IV Bags Market is estimated to be valued at US$ 3.7 billion in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Stricter regulations favoring non-PVC products: Stringent regulations banning the use of medical plastics containing hazardous chemicals like DEHP have been enacted in various countries. For instance, the Medical Device Regulation in EU prohibits the use of DEHP in medical devices from 2024. Similarly, the U.S. FDA has raised health concerns over PVC-based products. Such regulations promote the adoption of safer non-PVC alternatives in the IV bags market.
Advancements in polymer engineering: Material scientists are engaged in developing advanced eco-friendly polymers that can replace PVC for manufacturing IV solutions bags and sets. Polymers such as polyolefins and EVA minimize chemical leaching and provide desired properties. Innovations allowing large-scale production of non-PVC products will further expansion of this market in the coming years.
Growing prevalence of chronic diseases: Rise in lifestyle-related health conditions like diabetes and certain types of cancers that necessitate long-term intravenous drug delivery are fueling the demand for IV infusion containers. According to WHO, diabetes affects over 420 million people globally. Increasing disease burden worldwide presents remunerative opportunities within non-PVC IV bags market.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is relatively low due to high capital requirements and patents protecting existing technologies in IV bag production.
Bargaining power of buyers: The bargaining power of buyers is low to moderate since the market is fragmented with many buyers and there are no dominant buyers.
Bargaining power of suppliers: The bargaining power of suppliers is moderate since few manufacturers control the supply of key raw materials like PVC and non-PVC polymers used in IV bags.
Threat of new substitutes: The threat of new substitutes is low as non-PVC IV bags have established themselves as vital medical products with no cost-effective substitutes available.
Competitive rivalry: The competition in the market is high among the top players to gain market share and strengthen their product portfolio by developing customized non-PVC IV bags.
Key Takeaways
The Global Non-PVC IV Bags Market Demand is expected to witness high growth over the forecast period.
North America region currently dominates the market due to advanced healthcare infrastructure and growing prevalence of chronic diseases demanding IV treatments. The key players operating in the non-PVC IV bags market are Baxter, Sippex, B. Braun, Wipak, Amcor, and JW Life Science.
Key players operating in the non-PVC IV bags market are focusing on new product launches and strategic partnerships for business expansion. For instance, in 2022, Baxter launched Claria non-PVC IV bag for improved patient safety and environmental sustainability. The growing demand for customizable IV therapies and rising government support for avoiding toxic PVC materials are favoring the non-PVC IV bags market growth worldwide.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
